Author

R. T. Carback

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

R. M. Rubsamen· 3 shared C. V. Herst· 2 shared L. Wang· 2 shared P. E. Harris· 2 shared S. Burkholz· 2 shared S. Massey· 2 shared T. Brasel· 2 shared T. Hodge· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

R. M. Rubsamen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Survivin (BIRC5) peptide vaccine in the 4T1 murine mammary tumor model: a potential neoadjuvant T-cell immunotherapy for triple negative breast cancer.

S. R. Burkholz, C. V. Herst, R. T. Carback, P. E. Harris, R. M. Rubsamen

This study evaluates a survivin peptide vaccine in a 4T1 murine model, showing slower tumor growth and a gamma IFN Elispot response in vaccinated mice.

bioRxiv · Jul 25, 2022 · PreprintImmunology

Anti-IL-6 versus Anti-IL-6R BlockingAntibodies to Treat Acute Ebola Infection inBALB/c Mice: Potential Implications forTreating Cytokine Release Syndrome

R. M. Rubsamen, S. Burkholz, S. Massey, T. Brasel, T. Hodge, L. Wang, C. Herst, R. T. Carback, P. Harris

This study shows that early IL-6 neutralization with an anti-IL-6 mAb improves outcomes in Ebola-infected mice, suggesting potential benefits for treating cytokine release syndrome.

bioRxiv · Jun 20, 2020Immunology

An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors' CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

C. V. Herst, S. Burkholz, J. Sidney, A. Sette, P. E. Harris, S. Massey, T. Brasel, E. Cunha-Neto, D. S. Rosa, W. C. H. Chao, R. T. Carback, T. Hodge, L. Wang, S. Ciotlos, P. Lloyd, R. M. Rubsamen

The paper identifies a conserved Ebola Zaire epitope that provides protection in mice and suggests its potential application in COVID-19 vaccine design.

bioRxiv · Feb 25, 2020Immunology